Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Artiva Biotherapeutics to similar businesses based on the strength of its valuation, dividends, risk, analyst recommendations, earnings, profitability and institutional ownership.
Valuation & Earnings
This table compares Artiva Biotherapeutics and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Artiva Biotherapeutics | $250,000.00 | -$83.86 million | -1.31 |
| Artiva Biotherapeutics Competitors | $715.39 million | $10.31 million | -18.30 |
Artiva Biotherapeutics’ competitors have higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a breakdown of recent ratings for Artiva Biotherapeutics and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artiva Biotherapeutics | 1 | 4 | 2 | 0 | 2.14 |
| Artiva Biotherapeutics Competitors | 9931 | 15323 | 45717 | 1605 | 2.54 |
Artiva Biotherapeutics currently has a consensus price target of $24.80, indicating a potential upside of 534.27%. As a group, “Biotechnology” companies have a potential upside of 133.61%. Given Artiva Biotherapeutics’ higher probable upside, equities research analysts clearly believe Artiva Biotherapeutics is more favorable than its competitors.
Volatility & Risk
Artiva Biotherapeutics has a beta of 2.67, indicating that its stock price is 167% more volatile than the S&P 500. Comparatively, Artiva Biotherapeutics’ competitors have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.
Insider & Institutional Ownership
47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Artiva Biotherapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artiva Biotherapeutics | N/A | -45.32% | -41.38% |
| Artiva Biotherapeutics Competitors | -12,319.70% | -407.93% | -30.95% |
Summary
Artiva Biotherapeutics competitors beat Artiva Biotherapeutics on 8 of the 13 factors compared.
About Artiva Biotherapeutics
Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company’s lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies.
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
